Zhibei Biotech

Zhibei Biotech is a leading Chinese synthetic biology company specializing in de novo enzymatic DNA synthesis (EDS). Founded in 2021 by researchers from the Beijing Institute of Technology, the company utilizes a proprietary terminal deoxynucleotidyl transferase (TdT) technology to produce high-fidelity, long-fragment DNA sequences more efficiently than traditional chemical methods. Zhibei’s platform aims to eliminate the use of hazardous reagents and overcome the constraints of sequence complexity, providing critical infrastructure for mRNA vaccines, cell and gene therapies, and the emerging field of DNA data storage. Headquartered in Beijing, the company has secured significant venture capital funding from prominent firms such as Sequoia China and Matrix Partners China to scale its automated DNA synthesis hardware and services.